Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **Industry**: Biotechnology, specifically focusing on oral therapeutics in the Inflammatory and Immune (I&I) space - **Lead Drug**: PALI-2108, a PDE4 inhibitor developed for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis [2][3] Core Points and Arguments - **Drug Development Background**: - PALI-2108 was originally developed by Merck and later reformulated as a prodrug by Giiant Pharma [2] - The prodrug formulation is crucial as it mitigates severe adverse events associated with traditional PDE4 inhibitors, such as secretory diarrhea and CNS events [3][4] - **Clinical Development Status**: - Completed preclinical development and initiated clinical trials, treating 84 healthy volunteers and 5 ulcerative colitis patients [4][5] - Currently conducting a small cohort study in fibrostenotic Crohn's disease, with results expected by the end of the month [5] - Plans to file an IND for a definitive study in ulcerative colitis involving 196 patients by May, with patient treatment starting in early Q3 2026 and data readout by the end of 2027 [5][13] - **Market Potential**: - Crohn's disease and ulcerative colitis are multi-billion dollar markets, with fibrostenotic Crohn's disease being a significant unmet need as there are currently no approved therapies [14] - The company aims to differentiate itself with a dual-acting anti-inflammatory and anti-fibrotic drug, which is unique in the market [11][19] - **Competitive Landscape**: - Competitors include Agomab, which recently IPO'd at over $750 million, and other PDE4 inhibitors like AstraZeneca's roflumilast and Amgen's Otezla [12][14] - The company has developed a precision medicine test to identify potential responders to PALI-2108 [12] - **Efficacy and Safety Data**: - Early data from a phase 1B study showed promising results, including a 63% improvement in the modified Mayo score and significant reductions in inflammatory markers after just one week of treatment [24][42] - The drug demonstrated good safety and tolerability, with no serious adverse events reported even at high doses [44][45] Additional Important Content - **Financial Position**: - Completed a financing round in October 2025, providing sufficient funds to support definitive studies in both ulcerative colitis and fibrostenotic Crohn's disease, with a runway extending into 2029 [30][31] - **Team and Expertise**: - The company has built a strong team with experience from major pharmaceutical companies, enhancing its capability to execute its development plans [32] - **Regulatory Considerations**: - The company is evaluating whether to pursue a broader indication for Crohn's disease or focus specifically on fibrosing Crohn's, depending on the data from ongoing studies [33][34] - **Market Positioning**: - The company aims to position PALI-2108 as a faster-acting oral option in a market currently dominated by injectable therapies with lower remission rates [40][41] - **Long-term Durability of Response**: - The company is confident in the long-term efficacy of PALI-2108 based on historical data from other PDE4 inhibitors and ongoing studies [42][43] This summary encapsulates the key points discussed during the Palisade Bio FY Conference Call, highlighting the company's strategic direction, clinical development progress, market potential, and competitive landscape.

Summary of Palisade Bio FY Conference Call Company Overview - **Company**: Palisade Bio (NasdaqCM:PALI) - **History**: Established approximately 16 years ago, with a significant transformation occurring in summer 2023 after a phase 2 study yielded disappointing results. The company pivoted to focus on a PDE4 inhibitor acquired from Giiant Pharma, which was originally developed in Merck labs in Montreal [4][5]. Core Product and Mechanism - **Product**: PALI-2108, a prodrug PDE4 inhibitor designed to mitigate common adverse effects associated with traditional PDE4 inhibitors, such as diarrhea, headache, and nausea [7][9]. - **Mechanism**: The prodrug formulation allows for gut-restricted action, releasing the active ingredient in the distal gut, thus avoiding upper gastrointestinal issues. It has a long half-life and is administered once daily, which is unique among PDE4 inhibitors [10][11][12]. Clinical Development - **Phase 1A and 1B Studies**: Completed with promising results, including a 63% improvement in modified Mayo score in a small open-label study of 5 ulcerative colitis (UC) patients [18]. - **Phase II Plans**: Enrollment for the Phase II UC study is expected to start in Q3 2026, with top-line results anticipated by the end of 2027. The study aims to include 50-70% bio-experienced patients [23][39]. Market Opportunity - **Fibrostenosing Crohn's Disease (FSCD)**: Identified as a significant unmet need, with 75% of Crohn's patients requiring surgery for strictures. There are approximately 200,000 symptomatic patients in the U.S. alone [27]. - **Potential for Broader Applications**: The drug's mechanism may also be applicable to other inflammatory conditions, including COPD and IPF, due to its improved pharmacology and tolerability [43]. Financial Position - **Funding**: The company raised $138 million in a re-IPO, providing sufficient runway to conduct definitive studies in UC and Crohn's, with cash expected to last into 2029 [40]. Strategic Considerations - **Corporate Development**: The company is in early discussions with large pharmaceutical firms to raise awareness of its developments, preparing for potential partnerships as data becomes available [45]. Key Takeaways - **Innovative Approach**: PALI-2108's prodrug formulation represents a significant advancement in the treatment of inflammatory bowel diseases, aiming to improve patient tolerability and outcomes. - **Strong Pipeline**: The company is strategically positioned to address significant unmet needs in both UC and Crohn's disease, with plans for future studies and potential expansion into other therapeutic areas. - **Robust Financial Backing**: The recent funding provides a solid foundation for ongoing clinical trials and development efforts, enhancing the company's prospects for success in the competitive biotech landscape.

Core Points - The signing of a strategic cooperation agreement between Boehringer Ingelheim and the Macau University of Science and Technology Clinical Trial Center marks the initiation of the first new drug clinical trial in Macau, focusing on the efficacy and safety of nerandomilast for SARD-ILD [1][3][14] - This trial represents a significant milestone for Macau's clinical research landscape, transitioning from no clinical trials to the establishment of a structured clinical trial system [5][11][16] Group 1: Strategic Importance - The collaboration is seen as a pivotal step in completing the clinical research network of the Guangdong-Hong Kong-Macau Greater Bay Area, enhancing its position as an international hub for pharmaceutical innovation [3][8] - Boehringer's initiative aligns with its "Sustainable Development for Generations" strategy, emphasizing increased investment in research and development in China [7][8] Group 2: Challenges and Solutions - Macau has historically lacked the infrastructure and management systems for clinical trials, necessitating a comprehensive approach to build these from the ground up [5][12] - The collaboration involves multiple stakeholders, including Boehringer, MUST-CTC, and HKU-CTC, to address regulatory challenges and establish necessary frameworks for clinical trials [11][12] Group 3: Training and Capacity Building - A key focus of the project is on training personnel to ensure high-quality clinical trial execution, which is crucial for the development of Macau's clinical research capabilities [9][15] - The establishment of a compliant ethics committee and the development of standard operating procedures (SOPs) are essential steps taken to meet international clinical trial standards [12][13] Group 4: Long-term Vision - The project is not just about the immediate clinical trial but aims to lay the groundwork for future clinical research in Macau, enhancing local capabilities and attracting more pharmaceutical companies [14][16] - Public education on clinical trials is also emphasized to ensure community understanding and engagement, which is vital for the success of future research initiatives [15][16]

Core Viewpoint - The initiation of the clinical trial marks the completion of the "last piece of the puzzle" for the clinical research network in the Guangdong-Hong Kong-Macao Greater Bay Area [1] Group 1 - The first new drug clinical trial in Macau officially commenced on August 29 [1] - The trial is initiated by the multinational pharmaceutical company Boehringer Ingelheim and will be conducted at the Macau University of Science and Technology Clinical Trial Center [1] - This clinical trial is a double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of nerandomilast in patients with systemic autoimmune rheumatic disease-related interstitial lung disease [1]